Esophageal squamous cell carcinoma
Conditions
Interventions
Group A:Patients were treated with 2 cycles of the following drugs intravenously: camrelizumab (200 mg on day 1 every 3 weeks), nab-paclitaxel (260 mg/m2 on day 1 every 3 weeks), and carboplatin (area
Group B:Patients were treated with 4 cycles of the following drugs intravenously: camrelizumab (200 mg on day 1 every 3 weeks), nab-paclitaxel (260 mg/m2 on day 1 every 3 weeks), and carboplatin (area
Sponsors
People’s Hospital of Yangzhong
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Eligibility criteria for the trial included patients with pathologically confirmed esophageal squamous cell carcinoma between the age of 18 and older, with clinical stage II or III, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Exclusion criteria
Exclusion criteria: Patients were excluded if they had severe disease within the previous 5 years, active autoimmune disease, immunosuppressive therapy in the past two weeks, history of HIV, and esophageal perforation or hematemesis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathological complete response (PCR); | — |
Secondary
| Measure | Time frame |
|---|---|
| R0 resection rate;objective response rate (ORR);Disease-free survival (DFS);Overall survival (OS);Safety; | — |
Countries
China
Contacts
Public ContactJianping Wang
People’s Hospital of Yangzhong
Outcome results
None listed